27,324,727 Common Stock of Tenaya Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2022.
January 25, 2022
Share
27,324,727 Common Stock of Tenaya Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JAN-2022. These Common Stock will be under lockup for 181 days starting from 29-JUL-2021 to 26-JAN-2022.
Details:
The directors and officers, and substantially all securityholders have agreed that, without the prior written consent of Morgan Stanley & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co. on behalf of the underwriters, will not, and will not publicly disclose an intention to, during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus (the Restricted Period): offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock.
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of disease-modifying therapies that includes both gene therapies and small molecules discovered internally and developed using its product platforms and core capabilities to target defined sub-populations of patients with rare or prevalent forms of heart disease. Its product platforms include Gene Therapy, Cellular Regeneration and Precision Medicine to discover novel therapies for various forms of heart disease. The Company's lead product candidates include, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy, TN-301, a small molecule for heart failure with preserved ejection fraction, and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).